Education and positions MD, Hannover Medical School, 2000. PhD, Hannover Medical School, 2003. Clinical Resident, Dept. of Pediatric Hematology and Oncology, Hannover Medical School, 2002-2006. Postdoctoral Fellow, Dept. of Pediatric Hematology and Oncology, Hannover Medical School, 2004-2006. Research Group Leader, Dept. of Molecular Hematopoiesis, Hannover Medical School, 2006-2010. Assistant Professor of ‘Experimental Hematology‘, Dept. of Molecular Hematopoiesis, Hannover Medical School, 2010-2014. Offer, Full-time Faculty as Assistant Professor of Pediatric Hematology and Oncology, Weill Cornell Medical Center, Department of Pediatrics, New York, USA, 2010. Offer, Full Professor of ‘Stem Cells and Aging’, Ulm University, 2012. Offer, Full Professor of ‘Molecular Hematopoiesis’, Hannover Medical School, 2012. Full Professor of “Translational Oncology”, Dept. of Hematology, Oncology, and Clinical Immunology, University Hospital Tuebingen, since 2014. Clicinal and academic responsibilities Head Reference Laboratory for Research, Diagnostics and Biobanking of the European Branch of the Severe Chronic Neutropenia International Registry (SCNIR), since 2006. Since 2019 Board member, EU-funded Cooperation in Science and Technology (COST) Action “CA18233: European Network for Innovative Diagnosis and treatment of Chronic Neutropenias, EuNet-INNOCHRON”, since 2019. Advisory Board Member, SCNIR, since 2018. Research Group Leader, Dept. of Molecular Hematopoiesis, Hannover Medical School, Hannover, Germany, 2006 – 2010. Medical training in pediatrics, Hannover Medical School, 2002 – 2006. Research activity Main research interests include the understanding of the molecular pathomechanisms of severe congenital neutropenia and leukemia; establishment of the experimental in vitro and in vivo models of neutropenia, pre-leukemia and leukemia; identification of novel therapeutic approaches for neutropenia, pre-leukemia and leukemia; gene therapy of neutropenia; genetic diagnostics of neutropenia. Five selected references 1) Skokowa J. Circumventing Mutation to Nix Neutropenia. N Engl J Med. 2021;384(20):1956-8. PMID: 34010536. 2) Dannenmann B, Klimiankou M, Oswald B, Solovyeva A, Mardan J, Nasri M, Ritter M, Zahabi A, Arreba-Tutusaus P, Mir P, Stein F, Kandabarau S, Lachmann N, Moritz T, Morishima T, Konantz M, Lengerke C, Ripperger T, Steinemann D, Erlacher M, Niemeyer CM, Zeidler C, Welte K, Skokowa, J. hiPSC Model of Stage-Specific Leukemogenesis in Severe Congenital Neutropenia reveals BAALC as a Key Oncogene. Cell Stem Cell 28, 906-922.e906 (2021). PMID: 33894142. 3) Skokowa J, Dale DC, Touw IP, Zeidler C, Welte K. Severe congenital neutropenias. Nat Rev Dis Primers. 2017;3:17032. PMID: 28593997. 4) Skokowa J, Klimiankou M, Klimenkova O, Lan D, Gupta K, Hussein K, Carrizosa E, Kusnetsova I, Li Z, Sustmann C, Ganser A, Zeidler C, Kreipe HH, Burkhardt J, Grosschedl R, Welte K. Interactions among HCLS1, HAX1 and LEF-1 proteins are essential for G-CSF-triggered granulopoiesis. Nat Med 18, 1550-1559 (2012).. PMID: 23001182. 5) Skokowa J, Lan D, Thakur BK, Wang F, Gupta K, Cario G, Brechlin AM, Schambach A, Hinrichsen L, Meyer G, Gaestel M, Stanulla M, Tong Q, Welte K. NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway. Nat Med 15, 151-158 (2009). PMID: 19182797.